CURRENT NEWS

BioTeSyS selects Logos Technologies ALPHADAS^® eSource and pro-active EDC system to give clients real time access to study data.
Read more

Logos Technologies signs deal with second Singaporean site for ALPHADAS^® eSource and proactive EDC.
Read more

Logos Technologies signs another new client for its’ ALPHADAS^® CTMS product.
Read more

Logos and Medidata recently hosted a very informative webinar on Optimizing Early Phase Studies with Interoperable Clinical Development Solutions. Participants learnt how by integrating clinical development technologies they can optimize early phase studies by:

• Achieving greater cost savings and efficiencies with a single interoperable platform for all clinical data,
• Enabling better decision making through real-time visibility to cleaner data, validated at point of collection, and
• Easing study-progress monitoring and serious adverse event notifications as well as removing the need for source document verification.
If you missed out click here to request a complimentary recording of the webinar.

Logos Technologies joins Medidata Solutions Technology Partner Program. Interoperability Partnership Enables Seamless Flow of Data Between Logos Technologies ALPHADAS Early Phase Solution and Rave EDC/CDM System…. Read more

Community Research selects ALPHADAS^®, Logos Technologies Early Phase EDC System.
Read more

Richmond Pharmacology selects ALPHADAS^®, Logos Technologies Early Phase EDC System.
Read more

Fundación de Investigación de Diego selects ALPHADAS^®, Logos Technologies Early Phase EDC System.
Read more

CNS Network selects ALPHADAS^®, Logos Technologies Early Phase EDC System.
Read more

Spaulding Clinical's Innovations produce best quality in 240 Subject TQT Study.
Read more

Following Omnicomm Systems announcement in the press on 4th August 2009, Logos Holdings Ltd and Logos Technologies Inc were not affected by this and continue to own the Logos EDC assets and proprietary software known as ALPHADAS^® as previously. The Logos group continue to be owned by the same shareholders.

For any enquiries relating to this announcement or ALPHADAS^®, a world leading early phase EDC and Phase I site automation tool, please browse our website or for further information.

‘Duke’s Phase I Trials Go Electronic’ – A report by Barry Mangum, Director of Clinical Pharmacology, Duke Clinical Research Unit, and Associate Clinical Professor of Clinical Pharmacology, Duke University Medical Center.
Read more

Qualia Clinical Services selects ALPHADAS^® for Phase I Clinical Trials.
Read more

Logos wins Best IT Strategy at European Outsourcing Awards 2008.
Read more

Bio IT World - Duke goes with ALPHADAS^® for its early phase trials.
Read more

Duke licenses ALPHADAS^® Logos Technologies EDC software.
Read more

Three levels of integration for Exco Intouch, Logos Technologies, by Deborah Borfitz, eCliniqua.
Read more

Exco InTouch Partners with Logos Technologies to Improve Patient Recruitment in Clinical Trials.
Read more

Comprehensive NeuroScience / Comprehensive Phase One "Advanced technology to benefit patients and sponsors..."
Read more

NEWS ARCHIVE